ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-PO620

A Pilot Study on the Efficacy and Safety of Rituximab in the Maintenance of Remission in Adults with Minimal Change Disease

Session Information

Category: Glomerular Diseases

  • 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics

Authors

  • Ling, Wang, Department of Rheumatology and Clinical Immunology, Daping Hospital, Army Medical University (Third Military Medical University), Chongqing, China
  • Fei, Xiao, Department of Rheumatology and Clinical Immunology, Daping Hospital, Army Medical University (Third Military Medical University), Chongqing, China
  • Zi, Dai Huan, Department of Rheumatology and Clinical Immunology, Daping Hospital, Army Medical University (Third Military Medical University), Chongqing, China
Background

Minimal change disease (MCD) is a common etiology of nephrotic syndrome (NS). Steroid therapy is usually effective, but frequent relapses / steroid-dependent are therapeutic challenges. Rituximab ( RTX ) has shown promising results in inducing remission of relapsed and refractory MCD in adults, reducing the recurrence rate of the disease and prolonging the recurrence-free time. However, the efficacy and safety of RTX in maintaining the remission of adult-onset MCD have not been reported.

Methods

12 patients were confirmed by renal biopsy as MCD and received intravenous methylprednisolone (500mg/d, for 3 days) followed by oral methylprednisolone(0.8mg / kg / day). All patients achieved complete remission(CR) within 8 weeks,and then were randomised 1:1 to receive methylprednisolone(n=6) and RTX (n=6, 375mg/m2, intravenous, once weekly, 2 times in total). The methylprednisolone maintenance remission group(MMRG) continued oral methylprednisolone alone, with a reduction of 4 mg every 2-4 weeks. In the RTX maintenance remission group(RMRG), the methylprednisolone was reduced from the 9th week to discontinuation. The total exposure time of methylprednisolone was no more than 9 weeks.

Results

All patients presented with NS with a median urine protein quantification of 10.89 g/24h (5.9, 13.8 g/24h) and a median serum albumin level of 16.7 g/l (13.43, 19.85g/l). Their renal function was normal when MCD was diagnosed. Of the 6 patients with MCD in MMRG, there were three patients of relapsed during glucocorticoid reduction, 1 patient relapsed 1 month after glucocorticoid withdrawal, and 2 patients relapsed 2 months after glucocorticoid withdrawal. The Median duration of sustained remission was 7 months (4.75, 8 months, inter quartile range (IQR)). 6 patients in RMRG during a follow-up of 18.5 months (17, 20.5 months) had no relapse. Compared with the MMRG, the RMRG had significantly longer recurrence-free time (P<0.001) and less glucocorticoid exposure(P<0.001). No adverse events occurred in all patients.

Conclusion

RTX maybe an effective and safe treatment option for adult patients with first-episode MCD in maintaining disease remission and minimizing glucocorticoid exposure. However, high-quality clinical studies are needed to confirm the efficacy of rituximab in the maintenance of remission in first-episode MCD.

Funding

  • Government Support – Non-U.S.